Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Prevalence of Dementia and Other Frontotemporal Disorders
4.2.2 Increasing Drug Development Grants and Funding by Government as well as Non-Government Organisations
4.3 Market Restraints
4.3.1 Cost Issues and Lack of Awareness across Several Regions
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Drug Class
5.1.1 Cognitive Enhancers
5.1.2 Antipsychotics
5.1.3 Antidepressants
5.1.4 CNS Stimulants
5.1.5 Others
5.2 By Disease Indication
5.2.1 Frontotemporal Dementia
5.2.2 Primary Progressive Aphasia
5.2.3 Movement Disorders
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Online Pharmacies
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Apotex Inc.
6.1.2 AstraZeneca plc.
6.1.3 Auro Pharma
6.1.4 Johnson & Johnson
6.1.5 Mylan N.V.
6.1.6 Pfizer Inc.
6.1.7 Sanofi S.A.
6.1.8 Teva Pharmaceuticals USA, Inc.


7 MARKET OPPORTUNITIES AND FUTURE TRENDS